Sep 2026· Pakistan Journal of Pharmaceutical Sciences· Vol 40 1, pp.
285-292
· 0 citations· 30 references
Medicine
TL;DR
Quercetin showed protective effects in experimental UC models and these effects may be associated with modulation of the ERK-MMP signaling axis and further pathway-specific rescue experiments, pharmacokinetic studies and human-relevant models are required before this mechanism can be considered definitive or clinically translatable.
Abstract
Background
Ulcerative colitis is a relapsing inflammatory bowel disease driven by dysregulated immunity, epithelial barrier injury and microbial imbalance. Current therapies remain limited by relapse, adverse effects and incomplete response. Quercetin has anti-inflammatory and barrier-protective activities and ERK-MMP signaling may link inflammation to mucosal tissue damage.
Objectives
To evaluate whether the protective effects of quercetin in experimental ulcerative colitis (UC) are associated with modulation of ERK-MMP signaling, while avoiding causal overinterpretation beyond the animal and cellular evidence.
Methods
A dextran sulfate sodium (DSS)-induced mouse model and a lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage inflammatory model were used. Mice were allocated to the control, UC model and low-, medium- and high-dose quercetin groups. Disease activity index (DAI; unitless), colon length, histopathology, inflammatory cytokines and ERK/MMP-related molecules were evaluated by histological staining, ELISA, qRT-PCR and western blotting. In-vitro, quercetin was compared with the ERK phosphorylation inhibitor U0126 and an agonistic stimulus to explore pathway-related associations. The study was exploratory and did not include genetic rescue experiments or human validation.
Results
In DSS-treated mice, medium- and high-dose quercetin were associated with improved colon morphology, reduced DAI scores and partial restoration of colon length. Quercetin decreased pro-inflammatory cytokine expression and increased IL-10 expression. In both mouse colon tissues and LPS-stimulated RAW264.7 cells, quercetin was associated with reduced ERK1/2 activation and lower MMP-3 and MMP-9 expression, together with partial recovery of TIMP expression. These molecular changes were directionally consistent with the effects observed after ERK inhibition in-vitro.
Conclusion
Quercetin showed protective effects in experimental UC models and these effects may be associated with modulation of the ERK-MMP signaling axis. Further pathway-specific rescue experiments, pharmacokinetic studies and human-relevant models are required before this mechanism can be considered definitive or clinically translatable.
4-MC treatment significantly ameliorated the disease manifestations of DSS-induced colitis, including weight loss, increased DAI, and colon shortening, and may protect against DSS-induced colitis by enhancing intestinal barrier function, attenuating inflammatory and oxidative stress responses, and suppressing NLRP3 inf...
Zi-Qiang Yang, Hong-Xiang Yuan, Wei-Qing Chen et al.· Central European Journal of...· 0 citations
The study found that curcumin improves physiological indicators such as survival rate and body weight in UC-affected mice and alleviates pathological damage to intestinal tissue, and the therapeutic effects were more pronounced in the high-concentration curcumin group and the treatment group receiving curcumin combined...
Jing-Zhe Chen· BIO Web of Conferences· 0 citations
Concurrent administration of CUR exerted protective effects in a DSS-induced mouse model of UC by reducing inflammation and mucosal barrier injury and partially normalizing gut microbial and fecal metabolic profiles.
Fu Shu, Kai-Qi Chen, Ying-Jie Song et al.· Frontiers in Immunology· 0 citations
Introduction Inflammatory bowel disease (IBD) has an intricate pathophysiology that greatly impacts patients’ quality of life. Wumei Wan, a traditional Chinese medicinal formulation, exhibits specific therapeutic effects on IBD. Kaempferol (KF), an active ingredient in Wumei Wan, may significantly contribute to IBD. Me...
Hai-Xia Qi, Gui-Qun Zhou, Yun-Fei Dong et al.· Frontiers in Pharmacology· 0 citations